Jan 2, 2025 · Long-term follow-up showed that neoadjuvant pembrolizumab (Keytruda) and chemotherapy followed by surgery and adjuvant pembrolizumab continued to improve event-free (EFS) and overall survival (OS) compared with neoadjuvant chemotherapy and surgery alone in patients with resectable, early-stage non–small cell lung cancer (NSCLC), according to 4-year data from the phase 3 KEYNOTE-671 trial ...

Oct 12, 2024 · Adding weekly online MR-Linac (MRL) adaptive radiotherapy to temozolomide (Temodar) reduced clinical target volume (CTV) margins and limited exposure to normal brain tissue in patients with high-grade glioma, according to data from the phase 2 UNITED trial (NCT04726397).

Dr. Mohan discusses with Nurse Goff and Nurse Brigle the prevention and management of infections and neurological toxicities in patients receiving bispecific therapies, with a particular focus on the unique considerations of talquetamab targeting GPRC5D.

May 27, 2020 · Immunotherapy should be continued for up to 2 years in patients with metastatic lung cancer who are responding to the treatment, unless they experience disease progression or excessive toxicity, according to Gilberto de Lima Lopes, MD.

Dec 18, 2024 · “ctDNA testing looks for small pieces of DNA found in a patient’s blood that comes from cancer cells and tumors,” Grafton explains. “Screening for ctDNA can be used to detect cancer early, before symptoms occur, and also to monitor tumor growth in cases where cancer has already been detected.”

Jul 1, 2024 · Throughout the month of June, several cancer therapies have received FDA approval for diseases including thyroid cancer, myelodysplastic syndrome (MDS), colorectal cancer (CRC), endometrial cancer, and follicular lymphoma (FL).

Apr 26, 2024 · An oncology nurse details strategies used at his institution to reduce burnout — which can ultimately decrease the rate of “silent quitting.”

Sep 22, 2017 · Ninety percent of patients with cancer may experience chemotherapy-induced peripheral neuropathy (CIPN) during treatment, and many will see this adverse effect long after treatment ends.

Jul 10, 2024 · CAR T-cell therapy represents a significant advancement in the treatment of multiple myeloma, especially as its ability to provide deep and durable responses offers renewed hope to patients and healthcare providers alike, an expert said.

Nov 18, 2024 · The use of bispecific antibodies have brought landmark change for the treatment of relapsed/refractory multiple myeloma, and tend to be well-tolerated, explained Carrie Lechtenberger, APRN, FNP-C, CCM, OCN, CBCN.